Line Data Expected News Today

- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06,...

- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 -- Alterity Therapeutics , a...

ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia and SAN FRANCISCO, July 26,...

ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia and SAN FRANCISCO, July 26, 2023 -- Alterity Therapeutics , a...

CAP-1002 Cell Therapy Programs -Pivotal Phase 3, HOPE-3 Trial Initiation Underway- -Entered Exclusive Partnership with Nippon Shinyaku for...

Conference Call and Webcast Today at 4:30 PM Eastern Time Neurocrine Biosciences will hold a live conference call and webcast today at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Participants can access the live conference call by dialing 800-895-3361 (US) or 785-424-1062 (International) using the conference ID: NBIX. The webcast can also be accessed on Neurocrine Biosciences website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximate...

Share this article Share this article SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update on its business performance, including preliminary net product and inventory adjusted sales results of INGREZZA ® (valbenazine) for 2020, and key commercial and clinical development milestones for 2021. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, will discuss these updates as part of a webcast presentation at the 39 th Annual J...